FROM ABN NOTE:
"The licence agreement signed with Roche is non-exclusive and so this doesn’t
preclude Osmetech from selling OPTI TUBE itself. At this stage, we exclude revenues for organic sales of the OPTI TUBE".
FROM RNS 18/12/06:
"OPTI TUBE™ has generated much interest since its recent launch and a number of successful customer trials are yielding positive results that should lead to sales in the near future."
Additional revenue to forecast likely then "in the near future"..